Invitae Hereditary Prion Disease Test (PRNP NGS, Labcorp 900141)

A single gene laboratory-developed test that sequences PRNP, the gene linked to inherited prion disease, using next-generation sequencing, and reports single nucleotide variants, small insertions and deletions, and copy number changes. It began as an Invitae product and is now listed in the Labcorp catalogue as test 900141, after Labcorp bought select Invitae assets out of Chapter 11 in 2024. It is information on a test, not advice on whether to be tested.

Key facts

  • The test covers PRNP only; its order name is PRNP Single Gene Analysis and the catalogue CPT code is 81404.
  • Method is next-generation sequencing for single nucleotide variants, insertions, deletions and copy number variants, with reportable variants confirmed by validated orthogonal methods as needed.
  • Turnaround is 10 to 21 days from specimen pickup to release of the result to the ordering provider, with extra time possible for confirmatory or reflex testing.
  • Orders must include an attestation that the provider holds the patient's informed consent for genetic testing.
  • Accepted specimens are EDTA whole blood (4 mL preferred, 3 mL minimum), an Oragene Dx 500 saliva kit, two ORAcollect Dx buccal swabs, or extracted gDNA (5 ug at 50 ng/uL or higher).
  • Blood is stable for 90 days, saliva and buccal for 60 days at room temperature; blood, saliva and buccal samples must not be frozen.
  • Specimens are rejected if hemolyzed, too small, in the wrong container or temperature, or from a person who has had an allogeneic bone marrow transplant.
  • The test does not detect germline mosaicism, repeat expansions, large rearrangements or variants in other genes, and variant classification can change over time.
  • Labcorp states the test was developed and validated by Labcorp and is not FDA cleared or approved.
  • Labcorp's bid for select Invitae assets was approved by the bankruptcy court and announced on 7 May 2024, at USD 239 million cash plus other consideration.
  • Labcorp announced completion of the acquisition on 5 August 2024 and said it would combine Invitae technology with its specialty testing in oncology and select rare diseases; no individual tests were named.

Timeline

  1. 2024Invitae enters Chapter 11 in the US Bankruptcy Court for the District of New Jersey (reported in search results only).
  2. 2024Labcorp announces court approval of its bid for select Invitae assets.
  3. 2024Labcorp announces it has finalized the acquisition.
  4. 2026Labcorp catalogue page for test 900141 carries a 2026 copyright year; no revision date is shown.

Last checked 1 November 2026

Sources for this page